Form 4: Collegium Pharmaceutical Director John A. Fallon Receives Stock Grant

Director John A. Fallon of Collegium Pharmaceutical, Inc. was granted 7,693 restricted stock units (RSUs) on May 16, 2024, according to a recent SEC filing.

Summary

• John A. Fallon, a director at Collegium Pharmaceutical, Inc., received 7,693 restricted stock units (RSUs) on May 16, 2024.
• Each RSU represents the right to receive one share of Collegium Pharmaceutical's common stock.
• The RSUs vest on May 16, 2025, contingent upon Fallon's continued service as a director.
• Settlement of the RSUs will occur on the vesting date or, at Fallon's election, upon earlier termination of service, death, disability, or a change in control of the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of RSUs is a standard practice and indicates confidence in the director's continued service and the company's future.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and value creation.

Future Outlook

The vesting of the RSUs is contingent upon the director's continued service, suggesting an expectation of ongoing involvement with the company.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The RSU grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates